title: Genvir (Flamel Technologies).
abstract: Flamel Technologies is developing Genvir (formerly known as Viropump), a twice-daily controlled-release formulation of aciclovir, for potential use in the treatment of herpes simplex virus and varicella zoster virus infections. Genvir utilizes Flamel's proprietary Micropump technology, a microparticle-based drug delivery system designed to extend the time of absorption of drugs in the small intestine. The drug shows a comparable therapeutic efficacy to valaciclovir and famciclovir (both GlaxoSmithKline) [313393]. Phase III trials have been completed [302829]. In August 2000, Flamel filed for regulatory approval for the treatment of herpes in France, as a prelude to a pan-European approval [378641] and is preparing an IND application to begin clinical trials for genital herpes in the US [245970].
authors.affiliation: Utah State University, Institute for Antiviral Research, Logan 84322-5600, USA. honery@cc.usu.edu
authors.forename: D L
authors.initials: DL
authors.lastname: Barnard
mesh_terms: D000212:Acyclovir / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000998:Antiviral Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D002644:Chickenpox / Q000188:drug therapy; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006561:Herpes Simplex / Q000188:drug therapy; D006801:Humans; D019384:Nucleic Acid Synthesis Inhibitors; D013937:Thymidine Kinase / Q000037:antagonists & inhibitors
chemical_list: D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D019384:Nucleic Acid Synthesis Inhibitors; D013937:Thymidine Kinase; D000212:Acyclovir